This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Outcomes Liaisons (HOLs) Serve As Key Bridge Between Pharmaceutical Sector And Managed Care Groups

CHAPEL HILL, N.C., Feb. 24, 2013 /PRNewswire/ -- Managed care organizations and other payer types – including the government sector – have become the key customer groups for the pharmaceutical industry. To effectively convey a therapy's safety and cost effectiveness with managed care groups, the pharmaceutical sector has turned to Health Outcomes Liaisons (HOLs) to fill this critical communication role.

To help pharmaceutical executives better navigate and understand the activities of effective HOL programs at leading organizations, research and consulting firm Best Practices, LLC has published a research study on the emerging role of these specialized communicators. The study, " Health Outcomes Liaisons Excellence: How the HOL Function Drives Value Across the Healthcare Industry ," contains benchmarks and insights that illuminate how leading companies are delivering outstanding HOL services in an increasingly challenging business environment.  

The insights in the 63-page study identify future trends expected to impact the HOL function. It also discovers how executives -- tasked with supporting new products, but burdened with headcount constraints and limited resources -- can gain critical efficiencies through HOLs.

The benchmarking study also addresses issues such as the:

  • Structure and resources of Health Outcome Liaisons (HOL) programs, including staffing, budget, geographic span, oversight responsibility, and services provided
  • Scope, frequency, and timing of HOL services
  • Methods HOLs use to engage internal and external customers and build lasting relationships
  • Differences in roles of HOL, MSL, Key Account Manager and Sales staff

This benchmarking research drew participation from 23 HOL program leaders from 19 different pharmaceutical and medical device companies. In addition, deep-dive interviews were conducted with five participating companies to gather additional insights.

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1194.htm. For more information on other recent primary research studies, contact us at 919.403.0251 or visit our website at bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,103.70 -59.29 -0.33%
S&P 500 2,115.00 -8.48 -0.40%
NASDAQ 5,089.3010 -17.2920 -0.34%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs